June 2005
Investment Dealers' Digest;6/27/2005, Vol. 71 Issue 25, p44
Trade Publication
The article presents statistical information on investment banking in the sector of healthcare. Drug maker Wyeth Inc. may eliminate up to 750 of its full-time sales reps and restructure its operations by year end in an effort to trim costs. The Madison, New Jersey based Wyeth employs about 12,000 sales reps worldwide. The cuts would mostly hit its U.S. primary care division. The Bill & Melinda Gates Foundation pledged 5.4 million dollars last week to help biotechs research remedies for acute diseases in Third World countries, according to the journal "USA Today."


Related Articles

  • Fear of Deepening Woes. Quinn, William T. // njbiz;10/28/2002, Vol. 15 Issue 44, p28 

    Focuses on the finances of pharmaceutical company Wyeth for the third quarter of 2002. Earnings of the company; Price of the company's stocks; Analysis of the drop in Wyeth's profit margin; Share of the Premarin line of hormone replacement products in the company's sales.

  • Locally produced Effexor boosts Wyeth in 1Q 2003. Martinez, Marialba // Caribbean Business;5/22/2003, Vol. 31 Issue 20, p16 

    Focuses on the financial result of Wyeth in the first quarter of 2003 in the U.S. Amount of income increase; Impact of Premarin products on the revenue of the company; Budget for the development of hormone replacement drug.

  • INVESTMENT BANKING DATABASE: Healthcare.  // Investment Dealers' Digest;1/27/2003, Vol. 69 Issue 4, p42 

    Presents information about global health care underwriting volume as of January 21, 2003. Increase in net income of Pfizer Inc.; Law suit filed against Wyeth Inc. by its employee.

  • Mergers, Acquisitions Alter Balance of Power.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p114 

    The article reports on the announcement given by Pfizer Inc. that it will purchase Wyeth for an estimated amount of $68 billion. It mentions that the combined company is anticipated to emerge as one of the most diversified businesses in the international health care industry. Pfizer chief...

  • TOP STORIES.  // MondayMorning;10/22/2007, Vol. 15 Issue 42, p1 

    The article reports on net earnings of Pfizer Inc. and Wyeth Inc. for the third quarter of 2007. Pfizer Inc. reported a 77% drop in third-quarter profit as it booked a multibillion-dollar charge to exit its inhaled insulin franchise, Exubera, and posted lower sales of blockbuster cholesterol...

  • Drugmaker set to rebound.  // Crain's New York Business;1/7/2008, Vol. 24 Issue 1, p4 

    The article reports on the possible recovery of the financial performance of pharmaceutical company Wyeth in the U.S. The company's stock shed more than 10% of its value in 2007. The company has struggled to replace the drugs that contribute 25 percent of its $20 billion in revenues. Meanwhile,...

  • Pfizer to Acquire Wyeth, Cut Jobs, Close Sites. Ramesh, Deepti // Chemical Week;2/2/2009, Vol. 171 Issue 4, p25 

    The article reports on the acquisition of Wyeth by Pfizer which the two companies say will create one of the most diversified health care firms worldwide. Pfizer also plans to reduce its workforce and close five sites to cut costs. According to analysts, the merger is driven by the huge loss in...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;4/18/2009, Issue 576, p13 

    This section presents regulatory and health care updates. A briefing paper revealed the life-saving benefits of rotavirus vaccines. Saudi Arabia has added Wyeth's pneumococcal 7-valent CRM19 vaccine to its national immunization programme (NIP). Abbott Laboratories reduced the price of its...

  • Grey Healthcare secures Wyeth branding work.  // Media: Asia's Media & Marketing Newspaper;11/5/2004, p5 

    This article presents information related to corporate moves at Grey Healthcare Group Inc. Grey Healthcare has been awarded the medical marketing business for Wyeth Inc. without a pitch. The agency has hired Flora Amos to handle the new business. Amos who continues to work as a doctor,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics